There is a lot of drug development based on that theory and most of it came up empty and the one that didn’t came up empty was Abuhelm which is widely seen as one of the worst FDA drug approvals of recent years.
There are actually three amyloid antibodies that have shown some success: aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab. I think the FDA approval of aducanumab was absolutely the right decision, though it’s far from a miracle drug.
I spent about six months of my life buried in the Alzheimer literature. There’s a mountain of evidence for this hypothesis. Take a look at my previous comments if you’re curious.
There is a lot of drug development based on that theory and most of it came up empty and the one that didn’t came up empty was Abuhelm which is widely seen as one of the worst FDA drug approvals of recent years.
There are actually three amyloid antibodies that have shown some success: aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab. I think the FDA approval of aducanumab was absolutely the right decision, though it’s far from a miracle drug.
I spent about six months of my life buried in the Alzheimer literature. There’s a mountain of evidence for this hypothesis. Take a look at my previous comments if you’re curious.